2024年4月10日，歐盟食品安全局（EFSA）發布消息，歐盟食品安全局（EFSA）發布關于釀酒酵母MUCL 39885作為育肥牛飼料添加劑的授權更新申請的評估。
經過評估，專家小組得出結論，該添加劑在授權使用條件下對目標物種、消費者和環境是安全的。在授權更新的情況下，無需評估添加劑的功效。部分原文報道如下：
Following a request from the European Commission, EFSA was asked to deliver a scientific opinion on the assessment of the application for renewal of the authorisation of Saccharomyces cerevisiae MUCL 39885 (Biosprint®) as a feed additive for cattle for fattening (category: zootechnical; functional group: gut flora stabiliser). The applicant provided evidence that the additive currently in the market complies with the conditions of authorisation. The EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) confirmed that the use of Biosprint® under the current authorised conditions of use remains safe for the target species, the consumers and the environment. Taking into account the nature of the additive, the FEEDAP Panel concludes that the additive should be considered as a potential skin and respiratory sensitiser, and any exposure through skin and respiratory tract is considered a risk. The additive is not a skin/eye irritant. There is no need to assess the efficacy of Biosprint® in the context of the renewal of the authorisation.
經過評估，專家小組得出結論，該添加劑在授權使用條件下對目標物種、消費者和環境是安全的。在授權更新的情況下，無需評估添加劑的功效。部分原文報道如下：
Following a request from the European Commission, EFSA was asked to deliver a scientific opinion on the assessment of the application for renewal of the authorisation of Saccharomyces cerevisiae MUCL 39885 (Biosprint®) as a feed additive for cattle for fattening (category: zootechnical; functional group: gut flora stabiliser). The applicant provided evidence that the additive currently in the market complies with the conditions of authorisation. The EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) confirmed that the use of Biosprint® under the current authorised conditions of use remains safe for the target species, the consumers and the environment. Taking into account the nature of the additive, the FEEDAP Panel concludes that the additive should be considered as a potential skin and respiratory sensitiser, and any exposure through skin and respiratory tract is considered a risk. The additive is not a skin/eye irritant. There is no need to assess the efficacy of Biosprint® in the context of the renewal of the authorisation.
